Drug Trademark Dispute in India: Deceptive Similarity & Pharma Law Explained

A trademark dispute between Novo Nordisk and Dr. Reddy’s Laboratories (DRL) highlights strict Indian norms against deceptively similar drug names.

Background of the Dispute

• Novo Nordisk filed a case in the Delhi High Court alleging trademark infringement.
• The dispute arose over DRL’s proposed brand name ‘Olymviq’, claimed to be phonetically similar to ‘Ozempic’ for weight loss/obesity.
• DRL agreed to maintain the status quo, halting further manufacturing/marketing under the disputed name.

About the Weight loss Drugs

• Semaglutide-Based Therapies: Semaglutide is a GLP-1 receptor agonist used for Type-2 diabetes management and weight loss.
  • Marketed globally under brands like Ozempic and Wegovy.
• Generic Entry in India: DRL launched a generic semaglutide formulation under the brand ‘Obeda’.
  • The company explored additional brand names, leading to trademark disputes.
• Patent Expiry and Market Impact: Expiry of the semaglutide patent has enabled the entry of generic manufacturers.
  • Expected to increase competition, reduce prices, and improve accessibility of anti-diabetic and weight-loss drugs.

Enroll now for UPSC Online Course

Potential Violations in the Case

• Deceptive Similarity in Drug Names: Use of phonetically or visually similar trademarks (e.g., ‘Olymviq’ vs ‘Ozempic’) can mislead consumers.
  • Violates the Doctrine of Deceptive Similarity laid down in Cadila Healthcare Ltd vs Cadila Pharmaceuticals Ltd, which mandates stricter scrutiny for medicines.
• Violation of Trademark Law (India): Under the Trade Marks Act, 1999, Section 11 prohibits registration of marks causing confusion.
  • Even slight resemblance in pharmaceutical products can be restrained due to public health risks.
• Breach of International Naming Standards (INN System): Non-compliance with guidelines on International Non-Proprietary Names (INN).
  • Drug names derived from INNs must be distinct and non-deceptive to avoid misuse.
  • Section 13 of the Trademarks Act says that for drug trademarks, International Non-Proprietary Names (INN), which identifies the active pharmaceutical ingredient, are non-proprietary in nature, and cannot be monopolised.
• Public Health and Safety Risks: Misleading drug names can lead to wrong prescriptions, dispensing errors, and adverse health outcomes.
  • Courts emphasise that “drugs are poisons, not sweets”, requiring higher regulatory caution.
• Regulatory and Ethical Non-Compliance: Violates norms under bodies like Central Drugs Standard Control Organisation for safe drug approval and labelling.
  • Undermines ethical standards in pharmaceutical marketing and branding.

Implications of the Dispute

• Innovation vs Accessibility: Highlights the tension between patent protection (innovation incentives) and availability of affordable generics for wider public access.
• Rising Market Competition: Reflects intensifying competition in India’s pharmaceutical sector following patent expiries and entry of generic players.
• Strengthening Trademark: Reinforces the need for robust enforcement under the Trade Marks Act, 1999 to prevent confusion in critical healthcare products.
• Public Health Safeguards: Emphasises stricter regulation of drug naming to avoid medical errors and ensure patient safety. 

Check Out UPSC CSE Books

Visit PW Store

Conclusion 

The case underscores India’s strict pharmaceutical trademark regime, balancing patient safety, generic competition, and intellectual property protection in a rapidly evolving drug market.